Related Experiment Video

Updated: Sep 20, 2026

Development and Validation of an Ultrasensitive Single Molecule Array Digital Enzyme-linked Immunosorbent Assay for Human Interferon-α
08:26

Development and Validation of an Ultrasensitive Single Molecule Array Digital Enzyme-linked Immunosorbent Assay for Human Interferon-α

Published on: June 14, 2018

Oral interferon beta-1a in relapsing-remitting multiple sclerosis: a double-blind randomized study

C Polman1, F Barkhof, L Kappos

  • 1Department of Neurology, Free University Medical Center, de Boelelaan 1117, NL-1007 MB Amsterdam, The Netherlands. ch.polman@vumc.nl

Multiple Sclerosis (Houndmills, Basingstoke, England)
|August 21, 2003
PubMed
Abstract

Insights

Oral interferon beta-1a (IFNB-1a) did not demonstrate significant benefits for relapsing-remitting multiple sclerosis (RRMS) patients. The oral formulation was found to be safe and well-tolerated, with no notable differences in adverse events compared to placebo.

Area of Science:

  • Neuroimmunology
  • Clinical Neurology
  • Pharmacology

Background:

  • Parenteral interferon beta (IFNB) is a standard treatment for multiple sclerosis (MS).
  • Investigating oral IFNB-1a offers a potentially more convenient administration route.
  • Oral IFNB-1a has not been extensively studied for its efficacy and safety in RRMS.

Purpose of the Study:

  • To evaluate the safety and tolerability of three different doses of oral IFNB-1a.
  • To assess the effects of oral IFNB-1a on MRI lesions in relapsing-remitting MS (RRMS) patients.
  • To compare oral IFNB-1a efficacy against placebo over a six-month period.

Main Methods:

  • A multicenter, double-blind, randomized trial involving RRMS patients.
  • Patients received oral IFNB-1a (0.06, 0.6, or 6 MIU) or placebo every other day for six months.
  • MRI scans were used to quantify newly active lesions, enhancing lesion volume, and T2 lesion volume.

Main Results:

  • No significant differences in the cumulative number of newly active MRI lesions were observed between oral IFNB-1a doses and placebo.
  • Secondary efficacy endpoints showed minimal and inconsistent differences across treatment groups.
  • Oral IFNB-1a was safe and well-tolerated, with comparable adverse event profiles to placebo; no neutralizing antibodies were detected.

Conclusions:

  • Oral IFNB-1a demonstrated no beneficial effects on MRI lesions or clinical outcomes in RRMS patients.
  • The study found no evidence of systemic biological effects from oral IFNB-1a.
  • Oral IFNB-1a is a safe and well-tolerated treatment option for RRMS, although lacking efficacy.

Related Concept Videos

Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Blinding01:11

Blinding

Blinding is a commonly used method of not telling participants which treatment a subject is receiving. Blinding is a critical part of a randomized control trial or RCT. It reduces the bias that affects the results. In an RCT, blinding is used in the form of a placebo. A placebo effect occurs when untreated subjects falsely believe they have received the treatment and report improved symptoms. A placebo or a dummy treatment is administered to subjects to negate the bias caused by such an effect.